Company Filing History:
Years Active: 2024
Title: Carl Eric Schwartz: Innovator in CDK2 Inhibition
Introduction
Carl Eric Schwartz is a notable inventor based in Marblehead, MA (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that inhibit Cyclin-dependent kinase 2 (CDK2). With a total of 2 patents, Schwartz's work is pivotal in addressing CDK-related diseases and disorders.
Latest Patents
Schwartz's latest patents focus on CDK2 inhibitors and methods of using these compounds. The first patent provides compounds according to a specific formula, detailing their use in inhibiting CDK activity and treating related diseases. The second patent elaborates on the chemical compounds that inhibit CDK2 activity, along with their pharmaceutical compositions and methods for treating various disorders associated with CDK2.
Career Highlights
Carl Eric Schwartz is currently associated with Cedilla Therapeutics, Inc., where he continues to innovate in the field of medicinal chemistry. His work is characterized by a commitment to developing effective treatments for diseases linked to CDK2 activity.
Collaborations
Some of his notable coworkers include Louise Clare Kirman and Wojtek Michowski, who contribute to the collaborative efforts in research and development at Cedilla Therapeutics.
Conclusion
Carl Eric Schwartz's contributions to the field of CDK2 inhibition are significant, with his patents paving the way for advancements in the treatment of related disorders. His ongoing work at Cedilla Therapeutics, Inc. continues to impact the pharmaceutical landscape positively.